Literature DB >> 7595680

Lipoic (thioctic) acid increases brain energy availability and skeletal muscle performance as shown by in vivo 31P-MRS in a patient with mitochondrial cytopathy.

B Barbiroli1, R Medori, H J Tritschler, T Klopstock, P Seibel, H Reichmann, S Iotti, R Lodi, P Zaniol.   

Abstract

A woman affected by chronic progressive external ophthalmoplegia and muscle mitochondrial DNA deletion was studied by phosphorus magnetic resonance spectroscopy (31P-MRS) prior to and after 1 and 7 months of treatment with oral lipoic acid. Before treatment a decreased phosphocreatine (PCr) content was found in the occipital lobes, accompanied by normal inorganic phosphate (Pi) level and cytosolic pH. Based on these findings, we found a high cytosolic adenosine diphosphate concentration [ADP] and high relative rate of energy metabolism together with a low phosphorylation potential. Muscle MRS showed an abnormal work-energy cost transfer function and a low rate of PCr recovery during the post-exercise period. All of these findings indicated a deficit of mitochondrial function in both brain and muscle. Treatment with 600 mg lipoic acid daily for 1 month resulted in a 55% increase of brain [PCr], 72% increase of phosphorylation potential, and a decrease of calculated [ADP] and rate of energy metabolism. After 7 months of treatment MRS data and mitochondrial function had improved further. Treatment with lipoate also led to a 64% increase in the initial slope of the work-energy cost transfer function in the working calf muscle and worsened the rate of PCr resynthesis during recovery. The patient reported subjective improvement of general conditions and muscle performance after therapy. Our results indicate that treatment with lipoate caused a relevant increase in levels of energy available in brain and skeletal muscle during exercise.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7595680     DOI: 10.1007/BF00873552

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  37 in total

1.  Brain 31P-magnetic resonance spectroscopy in mitochondrial cytopathies.

Authors:  P Montagna; P Martinelli; P Cortelli; P Zaniol; E Lugaresi; B Barbiroli
Journal:  Ann Neurol       Date:  1992-04       Impact factor: 10.422

2.  31-P NMR characterization of the metabolic anomalies associated with the lack of glycogen phosphorylase activity in human forearm muscle.

Authors:  D Bendahan; S Confort-Gouny; G Kozak-Ribbens; P J Cozzone
Journal:  Biochem Biophys Res Commun       Date:  1992-05-29       Impact factor: 3.575

3.  Familial mitochondrial encephalomyopathy (MERRF): genetic, pathophysiological, and biochemical characterization of a mitochondrial DNA disease.

Authors:  D C Wallace; X X Zheng; M T Lott; J M Shoffner; J A Hodge; R I Kelley; C M Epstein; L C Hopkins
Journal:  Cell       Date:  1988-11-18       Impact factor: 41.582

4.  In vivo assessment of mitochondrial functionality in human gastrocnemius muscle by 31P MRS. The role of pH in the evaluation of phosphocreatine and inorganic phosphate recoveries from exercise.

Authors:  S Iotti; R Lodi; C Frassineti; P Zaniol; B Barbiroli
Journal:  NMR Biomed       Date:  1993 Jul-Aug       Impact factor: 4.044

5.  31P NMR study of improvement in oxidative phosphorylation by vitamins K3 and C in a patient with a defect in electron transport at complex III in skeletal muscle.

Authors:  S Eleff; N G Kennaway; N R Buist; V M Darley-Usmar; R A Capaldi; W J Bank; B Chance
Journal:  Proc Natl Acad Sci U S A       Date:  1984-06       Impact factor: 11.205

6.  Phosphorus magnetic resonance spectroscopy of patients with mitochondrial cytopathies demonstrates decreased levels of brain phosphocreatine.

Authors:  S M Eleff; P B Barker; S J Blackband; J C Chatham; N W Lutz; D R Johns; R N Bryan
Journal:  Ann Neurol       Date:  1990-06       Impact factor: 10.422

7.  Defective brain energy metabolism shown by in vivo 31P MR spectroscopy in 28 patients with mitochondrial cytopathies.

Authors:  B Barbiroli; P Montagna; P Martinelli; R Lodi; S Iotti; P Cortelli; R Funicello; P Zaniol
Journal:  J Cereb Blood Flow Metab       Date:  1993-05       Impact factor: 6.200

8.  In vivo muscle magnetic resonance spectroscopy in the clinical investigation of mitochondrial disease.

Authors:  P M Matthews; C Allaire; E A Shoubridge; G Karpati; S Carpenter; D L Arnold
Journal:  Neurology       Date:  1991-01       Impact factor: 9.910

9.  Cerebral metabolism in hyper- and hypocarbia: 31P and 1H nuclear magnetic resonance studies.

Authors:  O A Petroff; J W Prichard; K L Behar; D L Rothman; J R Alger; R G Shulman
Journal:  Neurology       Date:  1985-12       Impact factor: 9.910

10.  Investigation of human mitochondrial myopathies by phosphorus magnetic resonance spectroscopy.

Authors:  D L Arnold; D J Taylor; G K Radda
Journal:  Ann Neurol       Date:  1985-08       Impact factor: 10.422

View more
  8 in total

Review 1.  The mitochondrial myopathy encephalopathy, lactic acidosis with stroke-like episodes (MELAS) syndrome: a review of treatment options.

Authors:  Fernando Scaglia; Jennifer L Northrop
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

2.  In vivo assessment of human skeletal muscle mitochondria respiration in health and disease.

Authors:  B Barbiroli; S Iotti; R Lodi
Journal:  Mol Cell Biochem       Date:  1997-09       Impact factor: 3.396

Review 3.  Role of free radicals in the neurodegenerative diseases: therapeutic implications for antioxidant treatment.

Authors:  B Halliwell
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

Review 4.  Inborn errors of energy metabolism associated with myopathies.

Authors:  Anibh M Das; Ulrike Steuerwald; Sabine Illsinger
Journal:  J Biomed Biotechnol       Date:  2010-05-26

Review 5.  Treatment for mitochondrial disorders.

Authors:  Gerald Pfeffer; Kari Majamaa; Douglass M Turnbull; David Thorburn; Patrick F Chinnery
Journal:  Cochrane Database Syst Rev       Date:  2012-04-18

Review 6.  Current and Emerging Clinical Treatment in Mitochondrial Disease.

Authors:  Rory J Tinker; Albert Z Lim; Renae J Stefanetti; Robert McFarland
Journal:  Mol Diagn Ther       Date:  2021-03-01       Impact factor: 4.074

Review 7.  New treatments for mitochondrial disease-no time to drop our standards.

Authors:  Gerald Pfeffer; Rita Horvath; Thomas Klopstock; Vamsi K Mootha; Anu Suomalainen; Saskia Koene; Michio Hirano; Massimo Zeviani; Laurence A Bindoff; Patrick Yu-Wai-Man; Michael Hanna; Valerio Carelli; Robert McFarland; Kari Majamaa; Douglas M Turnbull; Jan Smeitink; Patrick F Chinnery
Journal:  Nat Rev Neurol       Date:  2013-07-02       Impact factor: 42.937

Review 8.  Monitoring clinical progression with mitochondrial disease biomarkers.

Authors:  Hannah E Steele; Rita Horvath; Jon J Lyon; Patrick F Chinnery
Journal:  Brain       Date:  2017-10-01       Impact factor: 13.501

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.